These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21122472)

  • 1. Diabetic nephropathy -- a multifaceted target of new therapies.
    Choudhury D; Tuncel M; Levi M
    Discov Med; 2010 Nov; 10(54):406-15. PubMed ID: 21122472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection in diabetes: role of glycemic control.
    Fioretto P; Bruseghin M; Berto I; Gallina P; Manzato E; Mussap M
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S86-9. PubMed ID: 16565255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic nephropathy.
    Ritz E
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection and treatment of diabetic nephropathy.
    Woredekal Y
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():999-1004. PubMed ID: 18806717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes.
    Nosadini R; Tonolo G
    J Nephrol; 2003; 16 Suppl 7():S42-7. PubMed ID: 14733300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of nephropathy in patients with type 2 diabetes.
    Critchley JA; Zhao HL; Tomlinson B; Leung W; Thomas GN; Chan JC; Cockram CS
    Chin Med J (Engl); 2002 Jan; 115(1):129-35. PubMed ID: 11930647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic nephropathy; clinical stage and prediction].
    Kaizu K; Komine N
    Rinsho Byori; 2001 Dec; 49(12):1205-11. PubMed ID: 11797389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
    Wolf G
    Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
    Susztak K; Raff AC; Schiffer M; Böttinger EP
    Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
    McCullough PA; Bakris GL; Owen WF; Klassen PS; Califf RM
    Am Heart J; 2004 Aug; 148(2):243-51. PubMed ID: 15308993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):1-14. PubMed ID: 16088846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of diabetic nephropathy.
    Raptis AE; Viberti G
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S424-37. PubMed ID: 11460589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.